Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05716945
Other study ID # 2022-500109-41-00
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date March 1, 2023
Est. completion date March 1, 2027

Study information

Verified date February 2023
Source Maastricht University Medical Center
Contact Sharista P.G. Baidjnath Panday, MD
Phone +31 6 40186513
Email sharista.baidjnath.panday@mumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: The cornea is the most transplanted tissue in the Netherlands, with more than 1,500 procedures performed each year. A minimally invasive technique called Descemet Membrane Endothelial Keratoplasty (DMEK) has become the preferred method in the past decade. The main advantage of DMEK over previous techniques is a low graft rejection rate (1-2% per year). Despite this, rejection prophylaxis after DMEK follows the same high potency regimen as previous techniques in the first year, and patients are burdened with indefinite immunosuppression. The current project, OPTIMISE, aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects. Corticosteroid eye drops are the mainstay of ocular immunomodulatory therapy. Their main side effect is a steroid-induced increase in intraocular pressure (IOP). It manifests in about one-fourth of patients within the first year after surgery and can lead to irreversible optic nerve damage and vision loss. Patients with IOP elevation require additional medications and hospital visits resulting in reduced quality of life and increased costs. The optimal dosing regimen in the first year after DMEK and whether patients may safely stop steroids after one year remains unknown. As a result, protocols in the Netherlands vary considerably from surgeon to surgeon. Patients are potentially over-treated in the short and long-term, resulting in undue burden for the patient and increased costs. Consequently, the Dutch Ophthalmology Society (NOG) identified the optimal short- and long-term immunosuppressive protocol for corneal transplantation as one of its Top 10 knowledge gaps, underscoring relevance for clinical practice. With this work, the investigators expect to address this knowledge gap to the benefit of our patients and society. Objective: The OPTIMISE study aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects. The hypothesis of this study is that Fluorometholone 0.1% in the first year and discontinuing medication in the second year is a cost-effective treatment strategy after DMEK. Study design: The design of this study is a randomized, controlled multicentre trial with a duration of 24 months. Study population: The study population will consist of 342 patients aged 21 years or older undergoing DMEK surgery in one eye. Intervention: All patients will receive Descemet's Membrane Endothelial Keratoplasty. Following this procedure, patients will be randomized into the following post-operative regime in two stages: STEP-I (Year 1): Control group: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months. Intervention group: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months. STEP-II (Year 2): Control Group: Half the patients in each study arm will use FML 0.1% daily. Intervention Group: Half the patients in each study arm will discontinue steroids. Main study parameters/endpoints: Primary outcomes: Step-I: IOP elevation compared to baseline Step-II: Endothelial cell loss (ECL) compared to pre-surgical baseline Secondary outcomes are: - Rejection free graft survival. - Patient reported outcome measures. - Incremental cost-effectiveness ratios, including a short term trial-based economic evaluation (TBEE) and a life-long model-based economic evaluation (MBEE) - Structural outcomes including corneal, central macular and retinal nerve fibre layer thicknesses, and optic nerve head imaging.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 342
Est. completion date March 1, 2027
Est. primary completion date March 1, 2026
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Patients aged 21 years or older registered on the NOTR as candidates for DMEK corneal transplantation Exclusion Criteria: - Inability to complete follow up or comply with study procedures - Previous corneal graft in the study eye - Known sensitivity or contraindication to the ingredients in the study medications - History of uveitis or herpetic keratitis - Human Leukocyte Antigen (HLA) typed allograft - Pregnancy (current and planned) or lactation - Use of other local or systemic immunosuppressive drugs

Study Design


Intervention

Drug:
Fluorometholone 0.1% Oph Susp
Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months. Year 2: Half the patients in each study arm will use FML 0.1% daily.
Dexamethasone 0.1% ophthalmic suspension
Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
Other:
Stop steroids
Half the patients in each study arm will discontinue steroids.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Difference of intraocular pressure elevation between the two arms Year 1
Primary Difference of endothelial cell loss (ECL) compared to pre-surgical baseline between arms Year 2
Secondary Difference of rejection free graft survival between arms 1-2 years
Secondary Differences of patient reported outcome measures between groups 1-2 years
Secondary Differences of incremental cost-effectiveness ratios, including a short term trial-based economic evaluation (TBEE) and a life-long model-based economic evaluation (MBEE) 1-2 years
See also
  Status Clinical Trial Phase
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT03016234 - IOP Changes With Different Anesthetic Agents During Laparoscopic Colorectal Surgery N/A
Completed NCT04863209 - Effect of Osteopathic Techiniques on Intraocular Pressure N/A
Completed NCT02646033 - Quantitative Rise in Intraocular Pressure in Steep Trendelenburg Position
Completed NCT03139708 - The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients Phase 1
Recruiting NCT02697825 - Intraocular Pressure Versus Optic Nerve Sheath Diameter N/A
Completed NCT02985567 - An Observational Study of the Use of Chloral Hydrate for Ophthalmic Procedures in Children N/A
Withdrawn NCT00837226 - Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure (IOP) N/A
Completed NCT02136589 - Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes Phase 4
Completed NCT03123614 - Loteprednol vs. Prednisolone and Fluorometholone Phase 4
Completed NCT05763056 - Effects of Intubation on Intra-ocular Pressure and Optic Nerve Sheath Diameter N/A
Completed NCT03359200 - Analysis of the Microbiota in Goldmann Applanation Tonometers at a Reference Service in Goiânia N/A
Completed NCT02816905 - Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery Phase 4
Withdrawn NCT02558309 - Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure N/A
Completed NCT01786954 - iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery N/A
Completed NCT00552019 - Intraocular Pressure (IOP) Assessed by Dynamic Contour Tonometer (DCT) and Goldman Applanation Tonometry (GAT) N/A
Completed NCT00428740 - Long-Term IOP Fluctuation and VF Progression After Triple Procedure N/A
Completed NCT04360369 - Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry N/A
Completed NCT04521140 - Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery Phase 4
Completed NCT05167773 - Clinical Study of the Topcon Tonometer TRK-3